C4 Therapeutics, Inc.
HealthcareNASDAQ:CCCC · NASDAQ Global Select
+$0.03 today
Vol 2.85M · Avg 2.75M
Management
Put operating results in leadership context
Review returns on capital, executive background, insider transactions, and growth quality to judge whether management is compounding value well.
Return Metrics
ROE, ROIC & ROA over time
ROE
-40.9%
avg -22.9%
ROIC
-31.4%
avg -29.2%
ROA
-29.2%
avg -24.6%
Analysis
ROA is currently the strongest return metric at -29.2% versus its period average of -24.6%. 0 of 3 return metrics are above their quality threshold, which helps indicate how efficiently the company turns capital and assets into profit.
Management
Key executives, compensation & ownership
| Name | Title | Compensation | Tenure | Age | Shares Owned | Ownership % |
|---|---|---|---|---|---|---|
Andrew J. Hirsch | Chief Executive Officer, President & Director | $1.38M | — | 55 | $1.08M | 1.31% |
Leonard J. Reyno | Chief Medical Officer | $1.03M | — | 64 | $379,803.00 | 0.46% |
Kendra Adams | Principal Accounting Officer, CFO, Head of Corporate Affairs & Treasurer | $869,511.00 | — | 49 | $400,479.00 | 0.48% |
Paige Mahaney | Chief Scientific Officer | $657,342.00 | — | 56 | $339,356.00 | 0.41% |
Kenneth C. Anderson | Co-Founder, Independent Director & Member of Scientific Advisory Board | $45,750.00 | — | 75 | $0.00 | <0.01% |
Nathanael S. Gray | Co-Founder & Member of Scientific Advisory Board | — | — | — | — | — |
Courtney Solberg | Senior Manager of Investor Relations | — | — | — | — | — |
Kelly Schick | Chief People Officer | — | — | 46 | $307,150.00 | 0.37% |
Christopher Nasveschuk | Senior Vice President of Chemistry | — | — | — | — | — |
Isabel Chiu | Senior Vice President of Strategic Alliances & Business Development | — | — | — | — | — |
Mark Mossler | Chief Accounting Officer | — | — | 52 | $75,184.00 | 0.09% |
Insider Trading
SEC Form 4 transactions — last 12 months
Buys
0
$0.00
Sells
1
$22,200.00
Net Sentiment
$22,200.00
Net selling
Most Active
REYNO LEONARD
1 transactions
Analysis
Insiders reported 0 buys worth $0.00 and 1 sells worth $22,200.00 over the last 12 months. That adds up to net selling of $22,200.00. REYNO LEONARD was the most active insider with 1 transactions.
Growth Analysis
Historical CAGR & forward analyst estimates
| Metric | 10yr | 5yr | 3yr | Fwd Est. |
|---|---|---|---|---|
| EPS | N/A | N/A | N/A | N/A2 analysts |
| Revenue | N/A | N/A | +13.3% | +65.9% (8yr)3 analysts |
| Net Income | N/A | N/A | N/A | N/A3 analysts |
| EBIT | N/A | N/A | N/A | N/A3 analysts |
Analysis
Recent growth has been strongest in Revenue at +13.3% over three years. Forward estimates point to Revenue at +65.9% (8yr), giving you a quick check on whether expectations are accelerating or cooling.
Competitors
Peer companies in the same sector
Cybin Inc.
CYBN
$413.02M
Armata Pharmaceuticals, Inc.
AMEX:ARMP
$278.27M
OmniAb, Inc.
NASDAQ:OABI
$270.34M
Codexis, Inc.
NASDAQ:CDXS
$218.15M
Molecular Partners AG
NASDAQ:MOLN
$154.17M
Insight Molecular Diagnostics Inc.
NASDAQ:IMDX
$150.58M
Milestone Pharmaceuticals Inc.
NASDAQ:MIST
$109.08M
PepGen Inc.
NASDAQ:PEPG
$101.68M
Sangamo Therapeutics, Inc.
NASDAQ:SGMO
$64.96M
Cassava Sciences, Inc.
SAVA
$63.77M
Who manages CCCC?
C4 Therapeutics, Inc. (CCCC) lists 11 active executives. The top listed executive is Leonard J. Reyno, Chief Medical Officer.
Are CCCC insiders buying or selling?
Recent insider activity shows net buying of $8.40M.
Explore More
Continue the stock analysis
Jump to another research area for this company.